Erstbeschreibung ALK-positives NSCLC bei herztransplantiertem Patienten

Zusammenfassung Immunsupprimierte Patienten stellen eine besondere Herausforderung in der thoraxonkologischen Therapie dar. Infektiöse Komplikationen unter Chemotherapie einerseits sowie fehlende Wirksamkeit der onkologischen Therapie unter Immuntherapie anderseits können die Therapieauswahl erschweren. ALK-Translokationen sind seltene Treibermutationen bei nicht-kleinzelligen Lungenkarzinomen. In der Literatur ist die Behandlung ALK-positiver transplantierter Patienten bislang nicht beschrieben.

• Publication year

  2025

• Venue

  Pneumologie

• Publication date

  2025-05-07

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/a-2715-8720PMID 41218626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Malignancies After Heart Transplantation

  2024cited by this paper
• Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.

  2024cited by this paper
• Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

  2024cited by this paper
• ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

  2024cited by this paper
• Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.

  2023cited by this paper
• Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.

  2023cited by this paper
• High incidence and reversible bradycardia events following alectinib initiation

  2022cited by this paper
• Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors

  2022cited by this paper
• Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

  2021cited by this paper
• Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

  2021cited by this paper
• Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation

  2021cited by this paper
• Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.

  2020cited by this paper
• First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

  2017cited by this paper
• Heart rate decrease during crizotinib treatment and potential correlation to clinical response

  2013cited by this paper
• Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

  2011cited by this paper
• The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension

  2011cited by this paper
• Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

  2010cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities.

  2004cited by this paper

• No citing papers are available for this paper.